Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
/ 124 items
#XY Analyst Up/Down↓
Wolfe Research Warns: Corcept Stock Pricing in Too Many Perfect Outcomes
Corcept stock looks overpriced despite strong drug sales; analysts warn expectations are too high and risks could drag shares lower.
Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
BTIG Calls Palvella’s 21% FDA-Driven Drop a Buying Opportunity
The FDA denied Breakthrough Therapy status for QTORIN. BTIG analysts view the decision as a short-term setback and maintain their Buy rating with a $215 price target.
Akari Therapeutics Strengthens Balance Sheet and Prepares Phase 1 as Maxim Raises Rating to Buy
Backed by promising Trop2 ADC preclinical data, new financing, and strong ADC market momentum.